Direct-to-Consumer Drug Programs May Complicate Medicaid Managed Care Pharmacy Benefits

The Trump administration is encouraging manufacturers to launch direct-to-consumer drug purchasing platforms that bypass traditional pharmacy benefit structures, with 10 manufacturers now offering such programs. While these cash-pay and potentially insurance-integrated platforms promise price transparency and patient choice, they create uncertainty for Medicaid MCOs around claims tracking, formulary management, adherence monitoring, and Stars performance measurement. The piece explores manufacturer design considerations but does not substantively address Medicaid-specific implications.

Pharmacy

This is outside commentary from Avalere, not part of Medicaid Monitor's independently scored news coverage.

More from Avalere